Actos Bladder Cancer Lawsuit

FDA Warns Actos May Increase Risk of Bladder Cancer

Actos (Pioglitazone) is an oral medication used, along with diet and exercise, to improve control of blood sugar in adults with type 2 diabetes by helping to reduce insulin resistance.  Actos, manufactured by Takeda Pharmaceuticals, is in a class of medications called thiazolidinediones, which work by increasing the body’s sensitivity to insulin, a natural substance that helps control blood sugar levels.

Many people are familiar with a similar diabetes drug, Avandia, and its associated risks of potential heart disease, strActosoke, and other complications.  As word spread about Avandia’s potential risks, Actos was often prescribed as an alternative.  However, recent research indicates that Actos may increase the risk of bladder cancer.

A five-year study involving nearly 200,000 patients showed that people who took Actos for 12 months or longer had a 40% increase in their risk of developing bladder cancer


Kogan & Associates is currently reviewing Actos lawsuits on behalf of individuals who have taken Actos to treat their diabetes, and have since been diagnosed with bladder cancer.  If you  have taken Actos and have been diagnosed with bladder cancer, call our Actos bladder cancer lawyers immediately to discuss your potential case.

Actos Bladder Cancer FDA Warning:

On June 15, 2011, the FDA published the following warning about Actos and bladder cancer:

“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”

While Actos is still being prescribed in the United States,  the risk of bladder cancer due to Actos usage has caused France to suspend the use of Actos and Germany has recommended that new patients not start Actos.


You may be entitled to compensation as a result of Takeda Pharmaceuticals’ failure to fully research Actos side effects before putting the drug on the market or warn the public about the possible increased risk of bladder cancer.  Please call our Actos bladder cancer attorneys immediately to discuss a potential Actos lawsuit.